Skip to main content
. 2012 Mar 7;1(3):206–220. doi: 10.5966/sctm.2011-0052

Figure 3.

Figure 3.

Effect of platelet-rich plasma and insulin on Akt and Erk1/2 activity and FGFR, IGF-1R, and IR transcript levels in human adipose-derived stem cells. (A, B): Representative blot (A) and densitometric analysis (B) of phosphorylated and total Akt, SREBP-1, and phosphorylated and total Erk1/2 in control, PRP (5% vol/vol), insulin (30 μM), and PRP + insulin-treated ASCs after 6 days. Data are mean ± SE. (C, D): Representative blot (C) and densitometric analysis (D) of phosphorylated and total Akt, SREBP-1, and phosphorylated and total Erk1/2 expression in control and PRP + insulin with or without Akt inhibitor wortmannin (10 μM) for 6 days. Data are mean ± SE. (E): Micrographs of Oil Red O staining and morphometric analysis of third passage ASCs cultured with PRP (5% vol/vol) + insulin (30 μM) in the presence of 10% fetal bovine serum and wortmannin (10 μM) for 6 days. Scale bar = 75 μm. Data are mean ± SE. (F): Real-time polymerase chain reaction (PCR) showing FGFR-1 and FGFR-2 mRNA in control, PRP (5% vol/vol), insulin (30 μM), and combined PRP + insulin-treated ASCs after 6 days. Data are mean ± SE. (G, H): Reverse transcriptase PCR (G) and densitometric analysis (H) documenting IGF-1R and IR transcripts in serum control, PRP (5% vol/vol), insulin (30 μM), and PRP + insulin-treated ASCs after 6 days. Data are mean ± SE. *, p < .05; **, p < .01; ***, p < .001. Abbreviations: ADU, arbitrary densitometric units; α-tub, α-tubulin; AU, arbitrary units; β2m, β-2-microglobulin; CTR, control; FGFR-1, fibroblast growth factor receptor-1; FGFR-2, fibroblast growth factor receptor-2; IGF-1R, insulin-like growth factor-1 receptor; ins, insulin; IR, insulin receptor; p-Akt, phosphorylated Akt; p-Erk1/2, phosphorylated Erk1/2; PRP, platelet-rich plasma; SREBP, mouse monoclonal anti-sterol regulatory element binding protein-1; w, wortmannin.